TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study
Brief Summary: Children with thalassemia may have high iron levels after receiving blood transfusions. These high iron levels can have damaging effects on the body, especially the heart. Conventionally only chelation therapy was given for prevention of iron buildup in the heart. However, current research has shown that another drug, amlodipine, also helps to slow down the deposition of iron in the heart. This study is designed to see if patients receiving amlodipine along with their regular chelation therapy have a slower rate of iron buildup in the heart when compared with patients who are receiving chelation only.


Options:
A: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm
B: Arm Label: Thalassemia; Type: N/A; Interventions: N/A
C: Arm Label: Standard Chelation & Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Standard Chelation, Drug: Amlodipine | Arm Label: Standard Chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chelation | Intervention Type: DRUG; Name: Standard Chelation; Assigned to Arm(s): Standard Chelation, Standard Chelation & Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Standard Chelation & Amlodipine
D: Arm Label: SPD602 (16mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Arm Label: SPD602 (32mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Intervention Type: DRUG; Name: SPD602 (FBS0701, SSP-004184); Assigned to Arm(s): SPD602 (16mg), SPD602 (32mg)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Study of Autologous Bone Marrow Mononuclear Cells Intrathecal Transplantation in Chronic Stroke
Brief Summary: The purpose of this study was to study the safety and effect of stem cell therapy on the functional recovery in patients with chronic stroke.


Options:
A: Arm Label: SB623 Implant (2.5M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Arm Label: SB623 Implant (5.0M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Arm Label: SB623 Implant (10.0M); Type: EXPERIMENTAL; Interventions: Biological: SB623 | Intervention Type: BIOLOGICAL; Name: SB623; Assigned to Arm(s): SB623 Implant (10.0M), SB623 Implant (2.5M), SB623 Implant (5.0M)
B: Arm Label: bone marrow stem cells; Type: OTHER; Interventions: Procedure: Infusion on autologous CD34+ stem cells into middle cerebral artery | Intervention Type: PROCEDURE; Name: Infusion on autologous CD34+ stem cells into middle cerebral artery; Assigned to Arm(s): bone marrow stem cells
C: Arm Label: Stem Cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow mononuclear cell transplantation | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow mononuclear cell transplantation; Assigned to Arm(s): Stem Cells
D: Arm Label: Bone marrow transplantation low dose; Type: EXPERIMENTAL; Interventions: Drug: Autologous bone marrow mononuclear cell intra-arterial injection | Arm Label: Bone marrow transplantation high dose; Type: EXPERIMENTAL; Interventions: Drug: Autologous bone marrow mononuclear cell intra-arterial injection | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Autologous bone marrow mononuclear cell intra-arterial injection; Assigned to Arm(s): Bone marrow transplantation high dose, Bone marrow transplantation low dose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Brief Summary: The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).


Options:
A: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Canagliflozin (JNJ-28431754) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 100 mg | Arm Label: Canagliflozin (JNJ-28431754) 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 100 mg | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 300 mg
D: Arm Label: Tight glucose control; Type: EXPERIMENTAL; Interventions: Drug: Insulin | Arm Label: Standard glucose control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Asp(B28)- | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Tight glucose control | Intervention Type: DRUG; Name: Insulin, Asp(B28)-; Assigned to Arm(s): Standard glucose control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations
Brief Summary: The objective of this study is to determine whether, in children receiving low-dose inhaled corticosteroids (ICS), quintupling the dose of inhaled corticosteroids at the onset of symptoms previously associated with upper respiratory illnesses and subsequent asthma exacerbations reduces the rate of severe asthma exacerbations treated with oral corticosteroids.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: Fluticasone 44 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone 44 mcg | Arm Label: Fluticasone 220 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone 220 mcg | Intervention Type: DRUG; Name: Fluticasone 44 mcg; Assigned to Arm(s): Fluticasone 44 mcg | Intervention Type: DRUG; Name: Fluticasone 220 mcg; Assigned to Arm(s): Fluticasone 220 mcg
C: Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS
D: Arm Label: steroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: prednisolone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: prednisolone | Intervention Type: DRUG; Name: prednisolone; Assigned to Arm(s): placebo, steroid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)
Brief Summary: The following trial hypothesis will be proved: In patients with atrial fibrillation and/ or pulmonary embolism standard anticoagulant treatment with coumadin/phenprocoumon is associated with accelerated coronary or valvular calcification as assessed by cardiac computed tomography compared to the new anticoagulant therapy with rivaroxaban.


Options:
A: Arm Label: Low-molecular-weight heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Low-molecular-weight heparin
B: Arm Label: Arm I (apixaban); Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Other: Questionnaire Administration | Arm Label: Arm II (dalteparin); Type: EXPERIMENTAL; Interventions: Drug: Dalteparin, Other: Questionnaire Administration | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm I (apixaban) | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Arm II (dalteparin) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (apixaban), Arm II (dalteparin)
C: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban or Marcumar | Arm Label: Marcumar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban or Marcumar | Intervention Type: DRUG; Name: Rivaroxaban or Marcumar; Assigned to Arm(s): Marcumar, Rivaroxaban

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Coaching Study
Brief Summary: The purpose of the study is to compare the effect of telemedical coaching versus telemedical control on HbA1c, weight, BMI, blood pressure, blood lipids, medication, nutrition, physical activity and quality of life in type 2 diabetes patients with poor glycaemic control.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedicine | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Telemedicine | Intervention Type: BEHAVIORAL; Name: Telemedicine; Assigned to Arm(s): 1, 2
B: Arm Label: Telephonic; Type: EXPERIMENTAL; Interventions: Behavioral: telephonic | Arm Label: Standard registry; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: telephonic | Intervention Type: BEHAVIORAL; Name: telephonic; Assigned to Arm(s): Standard registry, Telephonic
C: Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Health coaching and and Life-long Monitoring; Type: EXPERIMENTAL; Interventions: Procedure: Health Coaching and Life-long Monitoring | Intervention Type: PROCEDURE; Name: Health Coaching and Life-long Monitoring; Assigned to Arm(s): Health coaching and and Life-long Monitoring
D: Arm Label: Telemedical Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedical coaching, Other: Telemedicine | Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedical coaching | Intervention Type: BEHAVIORAL; Name: Telemedical coaching; Assigned to Arm(s): Telemedical Coaching, Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedical Coaching

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Post-traumatic Stress in ICU Survivors: A Pilot Randomized Controlled Trial of ICU Diaries
Brief Summary: The main objective of the study is to test the feasibility of the ICU diaries intervention in the ICU. The investigators do not have sufficient power to detect differences in the hypotheses below, but will use the present pilot study to inform sample size required to adequately power a follow-up randomized control trial.

(1) The investigators hypothesize that subjects exposed to a psychoeducation condition will have reduced rates of post-traumatic stress disorder (PTSD) compared to those experiencing treatment as usual (TAU). (2) The investigators hypothesize that compared to participants in the psychoeducation and TAU groups, those subjects exposed to an ICU diary, and those exposed to both ICU diary + psychoeducation conditions, will have significantly reduced rates of PTSD at follow-up. (3)The investigators hypothesize that participants exposed to the ICU diary + psychoeducation condition will have significantly lower rates of PTSD compared to those in the ICU diary alone condition.


Options:
A: Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Problem Solving Treatment; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): 2
C: Arm Label: ICU Diaries; Type: EXPERIMENTAL; Interventions: Behavioral: ICU Diary | Arm Label: Psychoeducation; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation | Arm Label: ICU Diary plus Psychoeducation; Type: EXPERIMENTAL; Interventions: Behavioral: ICU Diary, Behavioral: Psychoeducation | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ICU Diary; Assigned to Arm(s): ICU Diaries, ICU Diary plus Psychoeducation | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): ICU Diary plus Psychoeducation, Psychoeducation
D: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2. Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 2. Escitalopram | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mentalization-Based Treatment in Groups for Adolescents With Borderline Personality Disorder (BPD) or Subthreshold BPD Versus Treatment As Usual - the M-GAB Randomized Controlled Trial
Brief Summary: Background: Although it is now possible to diagnose Borderline Personality Disorder (BPD) in adolescents younger than 18 years according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V), and studies indicates that BPD can be reliably diagnosed in adolescence, only a few evidence based treatment programmes for adolescent BPD exists. Mentalization-based treatment (MBT), including group psychotherapy, has repeatedly shown to be effective in treating adult BPD, but in the case of adolescents, only individual MBT have been tested and found to be effective.

Aims/hypotheses: We will test whether group based MBT (MBT-G), including an introductory programme for patients (MBT-I) and their parents (MBT-P) is more effective than Treatment As Usual (TAU) in treating adolescents with BPD or subthreshold BPD.

Methods/Design: 112 patients referred to child and adolescent psychiatric clinics in Region Zealand will be randomized to either MBT or TAU. Inclusion criteria: Meeting DSM-V BPD-criteria at the threshold (five criteria) or sub threshold level (4 criteria). Follow-up will be at three and 12 months.

Discussion: Early intervention is especially important in relation to personality psychopathology and has long-term benefits for patients, their families and society. In addition to being cost effective, using the group modality in the treatment of BPD may have several advantages. This is the first Randomized Controlled Trial (RCT) to test the effectiveness of MBT in groups for adolescents.


Options:
A: Arm Label: Mentalization Based Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Mentalization Based Treatment | Arm Label: Treatment As Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment As Usual | Intervention Type: BEHAVIORAL; Name: Mentalization Based Treatment; Assigned to Arm(s): Mentalization Based Treatment | Intervention Type: BEHAVIORAL; Name: Treatment As Usual; Assigned to Arm(s): Treatment As Usual
B: Intervention Type: DRUG; Name: Topiramate; Assigned to Arm(s): N/A
C: Arm Label: Post Admission Cognitive Therapy (PACT); Type: EXPERIMENTAL; Interventions: Behavioral: Post Admission Cognitive Therapy (PACT) | Arm Label: Enhanced Usual Care (EUC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Post Admission Cognitive Therapy (PACT); Assigned to Arm(s): Post Admission Cognitive Therapy (PACT)
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Smartphone Assisted PST; Type: EXPERIMENTAL; Interventions: Other: Smartphone Assisted PST | Intervention Type: OTHER; Name: Smartphone Assisted PST; Assigned to Arm(s): Smartphone Assisted PST

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mentalization-Based Treatment in Groups for Adolescents With Borderline Personality Disorder (BPD) or Subthreshold BPD Versus Treatment As Usual - the M-GAB Randomized Controlled Trial
Brief Summary: Background: Although it is now possible to diagnose Borderline Personality Disorder (BPD) in adolescents younger than 18 years according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V), and studies indicates that BPD can be reliably diagnosed in adolescence, only a few evidence based treatment programmes for adolescent BPD exists. Mentalization-based treatment (MBT), including group psychotherapy, has repeatedly shown to be effective in treating adult BPD, but in the case of adolescents, only individual MBT have been tested and found to be effective.

Aims/hypotheses: We will test whether group based MBT (MBT-G), including an introductory programme for patients (MBT-I) and their parents (MBT-P) is more effective than Treatment As Usual (TAU) in treating adolescents with BPD or subthreshold BPD.

Methods/Design: 112 patients referred to child and adolescent psychiatric clinics in Region Zealand will be randomized to either MBT or TAU. Inclusion criteria: Meeting DSM-V BPD-criteria at the threshold (five criteria) or sub threshold level (4 criteria). Follow-up will be at three and 12 months.

Discussion: Early intervention is especially important in relation to personality psychopathology and has long-term benefits for patients, their families and society. In addition to being cost effective, using the group modality in the treatment of BPD may have several advantages. This is the first Randomized Controlled Trial (RCT) to test the effectiveness of MBT in groups for adolescents.


Options:
A: Arm Label: App-Condition; Type: EXPERIMENTAL; Interventions: Device: Monsenso DBT-app and IT monitoring program | Arm Label: Paperdiary-condition; Type: ACTIVE_COMPARATOR; Interventions: Other: Paper diary sheet | Intervention Type: OTHER; Name: Paper diary sheet; Assigned to Arm(s): Paperdiary-condition | Intervention Type: DEVICE; Name: Monsenso DBT-app and IT monitoring program; Assigned to Arm(s): App-Condition
B: Arm Label: Mentalization Based Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Mentalization Based Treatment | Arm Label: Treatment As Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment As Usual | Intervention Type: BEHAVIORAL; Name: Mentalization Based Treatment; Assigned to Arm(s): Mentalization Based Treatment | Intervention Type: BEHAVIORAL; Name: Treatment As Usual; Assigned to Arm(s): Treatment As Usual
C: Arm Label: CAMS treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): CAMS treatment, Treatment as usual
D: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): N/A

Answer: B